Agertoft L, Pedersen S E
Kolding Sygehus, børneambulatoriet.
Ugeskr Laeger. 2001 Nov 26;163(48):6746-50.
Short-term studies have shown that inhaled corticosteroids may retard the growth of children with asthma. The effect of long-term treatment on adult height is, however, uncertain.
We conducted a prospective study of children with asthma to examine the effect of long-term treatment with inhaled budesonide on adult height. We report on 211 children who have attained adult height: 142 asthmatic children treated with budesonide, 18 asthmatic control patients who have never received inhaled corticosteroids, and 51 healthy siblings of patients in the budesonide group, who also served as controls.
The children in the budesonide group attained adult height after a mean of 9.2 years of budesonide treatment (range 3-13 years) at a mean daily dose of 412 micrograms (range 110-877 micrograms). The mean cumulative dose of budesonide was 1.35 g (range 0.41-3.99 g). The mean differences between the measured and target adult heights were +0.3 cm (95% confidence intervals: -0.6; +1.2 cm) for the children treated with budesonide, -0.2 cm (95% confidence intervals: -2.4; +2.1 cm) for the control children with asthma, and +0.9 cm (95% confidence intervals: -0.4; +2.2 cm) for the healthy siblings. The adult height depended significantly (p < 0.001) on the child's height before budesonide treatment. Although growth rates were significantly reduced during the first years of budesonide treatment, these changes were not significantly associated with adult height.
Children with asthma who have received long-term treatment with inhaled budesonide attain normal adult height.
短期研究表明,吸入性糖皮质激素可能会延缓哮喘儿童的生长。然而,长期治疗对成人身高的影响尚不确定。
我们对哮喘儿童进行了一项前瞻性研究,以检验吸入布地奈德长期治疗对成人身高的影响。我们报告了211名已达到成人身高的儿童:142名接受布地奈德治疗的哮喘儿童,18名从未接受过吸入性糖皮质激素治疗的哮喘对照患者,以及布地奈德组患者的51名健康兄弟姐妹,他们也作为对照。
布地奈德组儿童在平均每日剂量为412微克(范围110 - 877微克)的布地奈德治疗9.2年(范围3 - 13年)后达到成人身高。布地奈德的平均累积剂量为1.35克(范围0.41 - 3.99克)。接受布地奈德治疗的儿童测量身高与目标成人身高的平均差异为+0.3厘米(95%置信区间:-0.6;+1.2厘米),哮喘对照儿童为-0.2厘米(95%置信区间:-2.4;+2.1厘米),健康兄弟姐妹为+0.9厘米(95%置信区间:-0.4;+2.2厘米)。成人身高显著取决于布地奈德治疗前儿童的身高(p < 0.001)。虽然在布地奈德治疗的最初几年生长速度显著降低,但这些变化与成人身高无显著关联。
接受吸入布地奈德长期治疗的哮喘儿童达到正常成人身高。